Everything You Need To Know About India's Cervical Cancer Vaccine

India will be launching their first self-developed cervical cancer vaccine

In India, the second most common cancer among women between the ages of 15 and 44 is cervical cancer

Cervical cancer is a malignancy of the cervix. This lethal illness poses a threat to all women.

Early detection increases the likelihood of successful treatment, long survival, and good quality of life.

The HPV vaccine offers defence against the strains of HPV that are most frequently linked to vulvar, vaginal, and cervical malignancies.

Development of the vaccine, known as the Quadrivalent Human Papillomavirus vaccine (qHPV), was carried out by the Department of Biotechnology and the Serum Institute of India (SII) (DBT)

Most likely, the vaccination will be considerably more reasonably priced. The government currently depends entirely on foreign manufacturers, and it costs ₹ 4,000 but should ideally cost between ₹ 200 - ₹ 400

Within the next few months, the government may make the vaccine available to girls aged 9 to 14 as part of the National Immunization Program